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Familial hypercholesterolemia (FH) is a genetic condition characterized by a high 
cholesterol concentration in the blood. The most frequent causes of FH are inherited 
defects in the Low Density Lipoprotein Receptor gene (LDLR) but, in a small percentage 
of patients, mutations in the apolipoprotein B gene (APOB) and in the propotein 
convertase subtilisin/kexin type 9 gene (PCSK9) are also responsible for FH. These 3 
genes are currently studied in the “Portuguese FH study”. From the 404 families with a 
clinical diagnosis of FH already studied only 48% of these have a mutation in one of the 
3 studied genes, so other gene defects must exist to explain the cause of 
hypercholesterolemia in the remaining families.  
The first aim was the exclusion of previously unidentified LDLR and APOB gene defects, 
as well as the exclusion of mutations in LDLRAP1 and CYP7A1 genes in patients with 
possible recessive hypercholesterolemia. A second aim was the whole sequencing of 
APOB gene, in 65 index patients without mutations in LDLR or PCSK9 genes or in 
fragments of exon 26 and 29 of APOB gene, by pyrosequencing, in order to identify the 
genetic cause of the hypercholesterolemia in these patients.  
CYP7A1 and LDLRAP1 genes were analysed by PCR and direct sequencing. A pool of the 
65 DNAs was sequenced by pyrosequecing method and a total of 227688 nucleotide 
reads were obtained, corresponding to a mean coverage of 35x/fragment/individual.  
No mutations were found in LDLRAP1 and CYP7A1 genes in 10 patients with possible 
recessive hypercholesterolemia. 
A total of 87 alterations were detected, being 27 described SNPs. From the 26 
alterations detected, only 12 were found and 4 of these had not been previously 
described. After family studies only one alteration did not co-segregate in the family, 
providing further evidence that 3 of the alterations found can be mutations causing 
disease, but functional studies are required to prove pathogenicity.  
 
Patients, in whom it was not possible to find the genetic cause of the 
hypercholesterolaemia, will continue to be studied, since all show a severe clinical 
phenotype of FH. 
